Aspirin may prevent cholangiocarcinoma: A case-control study from the United Kingdom

Digestive Diseases and Sciences

Volumn 59, Issue 7, 2014, Pages 1567-1572

  Burr, N E ^a   Talboys, R J ^b   Savva, S ^c   Clark, A ^d   Phillips, M ^b   Metcalfe, M ^c   Dennison, A ^c   Robinson, R ^c   Lewis, M P ^b   Rhodes, M ^b   Rushbrook, S ^b   Hart, A R ^d  

^a ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^b NORFOLK AND NORWICH UNIVERSITY HOSPITAL   (United Kingdom)

^c LEICESTER GENERAL HOSPITAL   (United Kingdom)

^d UNIVERSITY OF EAST ANGLIA   (United Kingdom)

Author keywords

Aspirin; Cholangiocarcinoma; Etiology; NSAIDs; Statins

Indexed keywords

ACETYLSALICYLIC ACID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; PRESCRIPTION DRUG;

ADULT; ARTICLE; BASAL CELL CARCINOMA; BILE DUCT CARCINOMA; CANCER PREVENTION; CANCER RISK; CASE CONTROL STUDY; CHEMOPROPHYLAXIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG INFORMATION; DRUG USE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; POPULATION EXPOSURE; PRESCRIPTION; PRIORITY JOURNAL; UNITED KINGDOM;

ADULT; AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CASE-CONTROL STUDIES; CHOLANGIOCARCINOMA; CONFIDENCE INTERVALS; FEMALE; GREAT BRITAIN; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LOGISTIC MODELS; MALE; MIDDLE AGED; ODDS RATIO; RISK FACTORS;

EID: 84903544426     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-014-3056-z     Document Type: Article

References (27)

1. Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics, 1998 [Internet]. CA Cancer J Clin. 1998;48:6-29. (Pubitemid 28045531)
2. Khan SA, Davidson BR, Goldin R, et al. Guidelines for the diagnosis and treatment of cholangiocarcinoma: consensus document [Internet]. GUT. 2002;51:VI1-VI9. (Pubitemid 35216840)
3. West J, Wood H, Logan RF, Quinn M, Aithal GP. Trends in the incidence of primary liver and biliary tract cancers in England and Wales 1971-2001. Br J Cancer. 2006;94:1751-1758. (Pubitemid 43924943)
4. Watanapa P, Watanapa WB. Liver fluke-associated cholangiocarcinoma. Br J Surg. 2002;89:962-970. (Pubitemid 34994687)
5. Burak K, Angulo P, Pasha TM, Egan K, Petz J, Lindor KD. Incidence and risk factors for cholangiocarcinoma in primary sclerosing cholangitis. Am J Gastroenterol. 2004;99:523-526. (Pubitemid 38524134)
6. Rosen CB, Nagorney DM, Wiesner RH, Coffey RJ Jr, LaRusso NF. Cholangiocarcinoma complicating primary sclerosing cholangitis [Internet]. Ann Surg. 1991;213:21-25.
7. Bergquist A, Broomé U. Hepatobiliary and extra-hepatic malignancies in primary sclerosing cholangitis. Best Pract Res Clin Gastroenterol. 2001;15:643-656. (Pubitemid 32747016)
8. Sorensen HT, Friis S, Olsen JH, et al. Risk of liver and other types of cancer in patients with cirrhosis: a nationwide cohort study in Denmark. Hepatology. 1998;28:921-925. (Pubitemid 28450250)
9. Shaib YH, El-Serag HB, Davila JA, Morgan R, McGlynn KA. Risk factors of intrahepatic cholangiocarcinoma in the United States: a case-control study. Gastroenterology . 2005;128:620-626. (Pubitemid 40585364)
10. Yamamoto S, Kubo S, Hai S, et al. Hepatitis C virus infection as a likely etiology of intrahepatic cholangiocarcinoma [Internet]. Cancer Sci . 2004;95:592-595. (Pubitemid 39089641)
11. Shin HR, Lee CU, Park HJ, et al. Hepatitis B and C virus, Clonorchis sinensis for the risk of liver cancer: a case-control study in Pusan, Korea [Internet]. Int J Epidemiol. 1996;25:933-940.
12. Kubo S, Kinoshita H, Hirohashi K, Hamba H. Hepatolithiasis associated with cholangiocarcinoma [Internet]. World J Surg. 1995;19:637-641.
13. Zhu AX, Lauwers GY, Tanabe KK. Cholangiocarcinoma in association with Thorotrast exposure. J Hepatobiliary Pancreat Surg. 2004;11:430-433. (Pubitemid 40069195)
14. Grainge MJ, West J, Solaymani-Dodaran M, Aithal GP, Card TR. The antecedents of biliary cancer: a primary care case-control study in the United Kingdom. Br J Cancer. 2009;100:178-180.
15. Jing W, Jin G, Zhou X, et al. Diabetes mellitus and increased risk of cholangiocarcinoma: a meta-analysis. Eur J Cancer Prev. 2012;21:24-31.
16. Han C, Wu T. Cyclooxygenase-2-derived prostaglandin E2 promotes human cholangiocarcinoma cell growth and invasion through EP1 receptor-mediated activation of the epidermal growth factor receptor and Akt. J Biol Chem. 2005;280:24053-24063. (Pubitemid 40884893)
17. Boonmasawai S, Akarasereenont P, Techatraisak K, Thaworn A, Chotewuttakorn S, Palo T. Effects of selective COX-inhibitors and classical NSAIDs on endothelial cell proliferation and migration induced by human cholangiocarcinoma cell culture [Internet]. J Med Assoc Thai. 2009;92:1508-1515.
18. Liu E, Sakoda LC, Gao YT, et al. Aspirin use and risk of biliary tract cancer: a population-based study in Shanghai, China. Cancer Epidemiol Biomark Prev. 2005;14:1315-1318. (Pubitemid 40656488)
19. Shimoyama S. Statins are logical candidates for overcoming limitations of targeting therapies on malignancy: their potential application to gastrointestinal cancers. Cancer Chemother Pharmacol. 2011;67:729-739.
20. Keyomarsi K, Sandoval L, Band V, Pardee AB. Synchronization of tumor and normal cells from G1 to multiple cell cycles by Lovastatin [Internet]. Cancer Res. 1991;51:3602-3609.
21. Jakobisiak M, Bruno S, Skierski JS, Darzynkiewicz Z. Cell cyclespecific effects of lovastatin. Proc Natl Acad Sci USA. 1991;1:3628-3632.
22. Kamigaki M, Sasaki T, Serikawa M, et al. Statins induce apoptosis and inhibit proliferation in cholangiocarcinoma cells. Int J Oncol. 2011;39:561-568.
23. World Health Organization. International statistical classification of diseases and related health problems. 10th revision. M8160/3.C. Geneva: World Health Oganization; 2007.
24. American Joint Committee on Cancer (AJCC). AJCC cancer staging manual. 6th ed. New York, NY: Springer; 2006.
25. Muller-Decker K, Furstenberger G. The cyclooxygenase-2-mediated prostaglandin signaling is causally related to epithelial carcinogenesis. Mol Carcinog. 2007;46:705-710. (Pubitemid 47255191)
26. Dannenberg AJ, Altorki NK, Boyle JO, et al. Cyclo-oxygenase 2: a pharmacological target for the prevention of cancer. Lancet Oncol. 2001;2:544-551. (Pubitemid 33586867)
27. Bhutta HY, Clark A, Holt S, et al. Oesophageal cancer-an aetiological investigation into the potential protective effect of statins in the UK General Practice Research Database (GPRD). Gastroenterology 2011;60:A36-A37.